JP2012502914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502914A5 JP2012502914A5 JP2011527043A JP2011527043A JP2012502914A5 JP 2012502914 A5 JP2012502914 A5 JP 2012502914A5 JP 2011527043 A JP2011527043 A JP 2011527043A JP 2011527043 A JP2011527043 A JP 2011527043A JP 2012502914 A5 JP2012502914 A5 JP 2012502914A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- scyllo
- inositol
- uric acid
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 claims 20
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 20
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 19
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 18
- 229940116269 uric acid Drugs 0.000 claims 18
- 239000002552 dosage form Substances 0.000 claims 16
- 201000005569 Gout Diseases 0.000 claims 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 201000001431 Hyperuricemia Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000013265 extended release Methods 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010007027 Calculus urinary Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 210000002565 arteriole Anatomy 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000004575 stone Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 208000008281 urolithiasis Diseases 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 208000002296 eclampsia Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9702308P | 2008-09-15 | 2008-09-15 | |
| US61/097,023 | 2008-09-15 | ||
| PCT/US2009/056985 WO2010031051A1 (en) | 2008-09-15 | 2009-09-15 | Methods of treatment of hyperuricemia and associated disease states |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502914A JP2012502914A (ja) | 2012-02-02 |
| JP2012502914A5 true JP2012502914A5 (OSRAM) | 2012-11-08 |
| JP5685192B2 JP5685192B2 (ja) | 2015-03-18 |
Family
ID=41319433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527043A Active JP5685192B2 (ja) | 2008-09-15 | 2009-09-15 | 高尿酸血症と関連病態の治療の方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8748496B2 (OSRAM) |
| EP (1) | EP2349280B1 (OSRAM) |
| JP (1) | JP5685192B2 (OSRAM) |
| AR (1) | AR073514A1 (OSRAM) |
| AU (1) | AU2009290612B2 (OSRAM) |
| CA (1) | CA2737163C (OSRAM) |
| ES (1) | ES2521674T3 (OSRAM) |
| TW (1) | TW201016208A (OSRAM) |
| WO (2) | WO2010031061A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| NZ562292A (en) | 2005-04-11 | 2009-11-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| KR101861547B1 (ko) | 2009-06-25 | 2018-07-02 | 크레알타 파마슈티칼스 엘엘씨 | 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트 |
| CN102726721A (zh) * | 2011-12-21 | 2012-10-17 | 聂存良 | 一种平衡性的微量元素排铅口服液 |
| US20160303050A1 (en) * | 2015-04-20 | 2016-10-20 | Twi Biotechnology, Inc. | Formulations containing diacerein and methods of lowering blood levels of uric acid using the same |
| EP3538135A4 (en) * | 2016-11-11 | 2020-07-29 | Horizon Pharma Rheumatology LLC | POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| CN109666687B (zh) * | 2018-12-14 | 2020-08-04 | 艾美科健（中国）生物医药有限公司 | 一种生物转化生产鲨肌醇的大肠埃希氏菌工程菌株及其构建方法和应用 |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998485A (en) | 1997-06-16 | 1999-12-07 | Cedars-Sinai Medical Center | Method for modulating immune response with inositol |
| US20080306166A1 (en) | 2004-11-17 | 2008-12-11 | Mclaurin Joanne | Compositions and Methods For Treatment of Disorders of Protein Aggregation |
| CN101686986A (zh) * | 2006-12-29 | 2010-03-31 | 诺尔姆奥克西斯公司 | 环多醇和其衍生物及其治疗应用 |
-
2009
- 2009-09-15 AU AU2009290612A patent/AU2009290612B2/en active Active
- 2009-09-15 US US12/560,113 patent/US8748496B2/en active Active
- 2009-09-15 AR ARP090103535A patent/AR073514A1/es unknown
- 2009-09-15 TW TW098131051A patent/TW201016208A/zh unknown
- 2009-09-15 WO PCT/US2009/057003 patent/WO2010031061A1/en not_active Ceased
- 2009-09-15 JP JP2011527043A patent/JP5685192B2/ja active Active
- 2009-09-15 ES ES09792556.4T patent/ES2521674T3/es active Active
- 2009-09-15 CA CA2737163A patent/CA2737163C/en active Active
- 2009-09-15 EP EP09792556.4A patent/EP2349280B1/en active Active
- 2009-09-15 WO PCT/US2009/056985 patent/WO2010031051A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502914A5 (OSRAM) | ||
| Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases | Chinese multidisciplinary expert consensus on the diagnosis and treatment of hyperuricemia and related diseases | |
| CN103429236B (zh) | 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 | |
| Liu et al. | The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3–5 | |
| JP2011520965A5 (OSRAM) | ||
| WO2004075852A2 (en) | Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions | |
| Schlesinger | Diagnosing and treating gout: a review to aid primary care physicians | |
| TW201414472A (zh) | Ｓｇｌｔ２抑制藥與抗高血壓藥之組合 | |
| AR073514A1 (es) | Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados | |
| Tsuruta et al. | Association between allopurinol and mortality among Japanese hemodialysis patients: results from the DOPPS | |
| WO2010009618A1 (zh) | 用于治疗高血压和代谢综合症的药物组合物及其应用 | |
| JP2013544870A (ja) | 肝障害のリスク管理に使用する薬剤の調製のためのドロネダロンの使用 | |
| Lee et al. | Comparison of age of onset and frequency of diabetic complications in the very elderly patients with type 2 diabetes | |
| WO2020200305A1 (zh) | 一种含羟基脲的药物组合物的应用 | |
| Turrisi et al. | Congestive heart failure during imatinib mesylate treatment | |
| Smith | The diagnosis and treatment of gout | |
| Feng et al. | [Retracted] Clinical Study of Heart Failure with Left Ventricular Ejection Fraction Regimen Treated with Entresto | |
| Shafique et al. | Renal artery stenosis and cardiovascular risk | |
| Tie et al. | Effects of febuxostat in different doses on uric acid, inflammatory factors of serum and knee articular cavity, endothelin-1, and oxidative stress in patients with a gout-a comparative study | |
| Mencarelli et al. | Chronic kidney disease | |
| CN101229372A (zh) | 一种治疗高血压的药物组合物 | |
| Sattur et al. | Renal artery stenosis-an update | |
| CN102485227B (zh) | 一种药物组合物及其用途 | |
| Yang et al. | Impact of Sacubitril/Valsartan on Cardiac Structure and Blood Levels of miRNA-328 and NT-proBNP in Patients with CHD and Chronic Heart Failure | |
| Capote et al. | Pathophysiology of heart failure |